@entity1499 ( @entity1500 ) is still the gold standard in the treatment of @entity309 and is used worldwide in more than 0.5 million @entity1 with @entity309 . Much hope is currently associated with the individualization of therapy provided to @entity309 @entity1 . The search is underway for biochemical and clinical markers that would be useful in predicting good response to @entity1500 therapy. Along with clinical factors, genetic predisposition may also be helpful. Polymorphism of genes participating in @entity1500 metabolism may affect the drug   s efficacy and the rate of adverse effects. Pharmacogenetic studies may contribute to more effective individualization of therapy for @entity309 @entity1 . There are many potential enzymes and transport proteins present in polymorphic forms, which are involved in transport of @entity1500 into the cell, its metabolism and elimination from the cell. There is a chance that in the future through individualized therapy we will be able to customize therapy (type of drug, dose, route of administration) to the molecular subtype of the disease and the genotype of the @entity1 . @entity1 with a specific type of polymorphism would require more frequent monitoring of the efficacy and safety of treatment. Note, however, that genetic predisposition is only one of the factors contributing to differences in pharmacotherapy in individual @entity1 .

[The importance of pharmacogenetic tests in evaluation of the effectiveness of @entity1499 treatment in XXXX (part 1)].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
